319 articles by Michael Gibney

• J&J’s blockbuster Spravato is setting the stage for managing psychedelics’ risks

  March 3, 2026

• Biohaven says FDA roadblocks leave rare disease patients in limbo

  Feb. 26, 2026

• Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

  Feb. 19, 2026

• Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

  Feb. 12, 2026

• A protein model designed for space could expand pharma’s definition of ‘druggability’

  Feb. 11, 2026

• Big Pharma CEOs set sights on massive growth in years to come

  Feb. 5, 2026

• Investors crave safer, market-ready biotech bets, widening the early-stage funding gap

  Feb. 3, 2026

• Politicization runs deeper than ever at FDA, risking long-term impacts

  Jan. 29, 2026

• A potential gene therapy for heart failure is an approach decades in the making

  Jan. 27, 2026

• US drug pricing policies are ‘red lights’ for investors, and China beckons

  Jan. 22, 2026

• It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?

  Jan. 15, 2026

• 3 positive trends for Massachusetts’ biopharma sector

  Jan. 13, 2026

• Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

  Jan. 8, 2026

• Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

  Dec. 19, 2025

• 5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.

  Dec. 16, 2025

• Pharma’s top deals in 2025

  Dec. 11, 2025

• How Lilly uses Big Pharma heft to lift up-and-coming biotechs

  Dec. 9, 2025

• BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?

  Dec. 4, 2025

• Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons

  Dec. 2, 2025

• Pharma faces a critical ‘turning point’ in 2026, years in the making

  Nov. 21, 2025

• RNAi looked doomed to fail — until Alnylam’s science chief found a way

  Nov. 13, 2025

• Why Pfizer and Novo are duking it out over weight loss startup Metsera

  Nov. 6, 2025

• Biogen’s yearslong lupus R&D journey could soon pay off

  Nov. 4, 2025

• How Trump’s do-or-die agenda is impacting Big Pharma’s CEO chatter

  Oct. 30, 2025

• Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience

  Oct. 28, 2025

• Massachusetts biotech hub is limping amid layoffs and low investment

  Oct. 23, 2025

• In the Salesforce vs. Veeva saga, the clock is ticking for drugmakers

  Oct. 21, 2025

• J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio

  Oct. 16, 2025

• Nobel Prize victory spotlights immunology’s value in pharma

  Oct. 9, 2025

• Overcoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’

  Oct. 7, 2025

• Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?

  Oct. 2, 2025

• Can a multibillion-dollar deal put Pfizer in the obesity big leagues?

  Sept. 25, 2025

• Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics

  Sept. 23, 2025

• How pharma can play a role in the $1 trillion healthcare reinvention

  Sept. 18, 2025

• Biotech’s VC slowdown forces young drugmakers to adapt in the ‘valley of death’

  Sept. 17, 2025

• Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

  Sept. 11, 2025

• Can new Alzheimer’s tests help clear the way for the next generation of therapies?

  Sept. 9, 2025

• Why drugmakers may need to borrow from quantum theory to confront tariff and pricing threats

  Sept. 3, 2025

• How AI advances will shape the drugmaker of the future

  Sept. 2, 2025

• AbbVie dives back into the neuro pool with a $1.2B psychedelics play

  Aug. 26, 2025

• The biggest Big Pharma losers in the first half of 2025

  Aug. 21, 2025

• In cell therapy, cost is a hot issue. The industry might need a cold solution.

  Aug. 19, 2025

• With scrapped mRNA funding, a vaccine maker finds a silver lining

  Aug. 14, 2025

• Puerto Rico’s ongoing journey from manufacturing hub to innovation enterprise

  Aug. 12, 2025

• Inside AstraZeneca’s long-game strategy in lung cancer

  Aug. 7, 2025

• Let’s make a deal? Big Pharma execs express varying views on their M&A future

  Aug. 5, 2025

• Merck & Co. assembles an Alzheimer’s comeback with a next-gen precision focus

  Aug. 1, 2025

• From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity

  July 25, 2025

• Novartis’ Zolgensma sales fall again as gene therapy market woes persist

  July 22, 2025

• J&J accelerates past Stelara’s fall with better-than-expected portfolio growth

  July 17, 2025

• Biotech IPO momentum gained steam last year, but market ‘turmoil’ has slowed the train again

  July 15, 2025

• Pricing watchdog will take on the rising cost of drugs at launch

  July 10, 2025

• Is biopharma dealmaking getting hot again?

  July 8, 2025

• AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

  July 1, 2025

• Biopharma is on edge about NIH funding cuts and what the future holds for research

  June 26, 2025

• How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

  June 24, 2025

• Biotech’s turning point: for every challenge, an opportunity in disguise

  June 20, 2025

• Can ‘reputational pull’ save biotech from pharma’s image problem?

  June 12, 2025

• The former Wall Street analyst shaping Novartis’ big-picture strategy

  June 10, 2025

• With ADCs on the rise, drugmakers embrace a new oncology pillar

  June 6, 2025

• How leading oncology drugmakers set the stage for future advances

  June 3, 2025

• With new Alzheimer’s blood test cleared, a potential vaccine could be on the horizon

  May 28, 2025

• Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change

  May 22, 2025

• A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

  May 15, 2025

• With the breakneck speed of cancer breakthroughs, oncologists feel left behind. Can Big Pharma chime in?

  May 13, 2025

• Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

  May 8, 2025

• On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

  May 6, 2025

• Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

  May 1, 2025

• US backlash against mRNA vaccines could hinder scientific progress

  April 29, 2025

• Flagship’s latest venture reflects more than 25 years of leaping into the unknown

  April 24, 2025

• Beyond the drug: Closing the knowledge gap for injectable diabetes meds

  April 22, 2025

• Pharma’s capital allocation could shift as tariffs threaten an already fragile profit model

  April 14, 2025

• Trump’s tariff tirade and sudden calm keep Big Pharma on its toes

  April 10, 2025

• Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.

  April 8, 2025

• Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’

  April 1, 2025

• How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

  March 27, 2025

• Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

  March 20, 2025

• How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

  March 18, 2025

• Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

  March 13, 2025

• Pricing transparency is in the spotlight — and that could be good news for drugmakers

  March 11, 2025

• The time is ripe for pharma M&A. Why are drugmakers holding out?

  March 6, 2025

• New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

  March 4, 2025

• AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

  Feb. 27, 2025

• Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

  Feb. 25, 2025

• Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

  Feb. 20, 2025

• Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split

  Feb. 13, 2025

• Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma

  Feb. 11, 2025

• With uncertainty roiling Big Pharma, execs are placing lower-risk bets

  Feb. 6, 2025

• Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid

  Feb. 4, 2025

• RFK Jr. faces reconciliation of past vaccine statements at Senate HHS hearing

  Jan. 30, 2025

• Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt

  Jan. 28, 2025

• J&J is all in on tau-targeted Alzheimer’s candidates. Will the approach lead to more effective treatments?

  Jan. 23, 2025

• By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years

  Jan. 16, 2025

• Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?

  Jan. 14, 2025

• After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

  Jan. 9, 2025

• How pharma was instrumental in President Jimmy Carter’s global health efforts

  Jan. 3, 2025

• Merck’s RSV antibody could soon paddle into the rough waters of a crowded market

  Dec. 19, 2024

• Maternal mortality trends remain dire — and researchers face an uphill battle to solve them

  Dec. 17, 2024

• Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

  Dec. 12, 2024

• GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.

  Dec. 10, 2024

• How Astellas juggles the moving parts of cancer precision medicine development

  Dec. 5, 2024

• How Alexion markets a rare disease drug by ‘starting with the end in mind’

  Dec. 3, 2024

• An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

  Nov. 26, 2024

• Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals

  Nov. 21, 2024

• What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine

  Nov. 19, 2024

• Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past

  Nov. 14, 2024

• Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in

  Nov. 7, 2024

• Two former Alexion leaders fight through a tough market to maintain a rare disease biotech

  Nov. 5, 2024

• 2024 PharmaVoice 100s: Cancer Care Visionaries

  Nov. 1, 2024

• Big Pharma earnings hang hope on the next generation of blockbusters

  Oct. 31, 2024

• 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers

  Oct. 30, 2024

• How AZ’s respiratory wins are ramping up for a bigger prize in COPD

  Oct. 29, 2024

• 2024 PharmaVoice 100s: Biotech Pathfinders

  Oct. 23, 2024

• With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble

  Oct. 22, 2024

• As new Alzheimer’s biomarkers come into play, here’s where the money is going

  Oct. 17, 2024

• AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential

  Oct. 15, 2024

• Regeneron takes the long-haul approach to oncology, stumbles and all

  Oct. 10, 2024

• Flu vaccination rates are falling despite record child deaths. Can innovation save the day?

  Oct. 3, 2024

• Top pharma and biotech conferences in the second half of 2025 and beyond

  Oct. 1, 2024

• Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters

  Sept. 26, 2024

• Want better cancer treatments? Make biopharma more like Silicon Valley

  Sept. 24, 2024

• At J&J, oncology R&D meets commercial strategy in a quest for new standards of care

  Sept. 19, 2024

• How a radiopharma up-and-comer builds momentum in a surging space

  Sept. 17, 2024

• How Lilly’s sustainability goals come face to face with massive growth

  Sept. 12, 2024

• A new way of determining a drug’s value — with health equity in mind

  Sept. 10, 2024

• A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market

  Sept. 4, 2024

• Their Alzheimer’s treatment worked — but shares fell anyway

  Aug. 29, 2024

• As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk

  Aug. 27, 2024

• 23andMe inches closer to cancer immunotherapy, guided by its genetic database

  Aug. 20, 2024

• Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through

  Aug. 15, 2024

• A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients

  Aug. 13, 2024

• Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half

  Aug. 8, 2024

• Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback

  Aug. 6, 2024

• 7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run

  July 30, 2024

• Gilead eyes ‘ending the HIV epidemic’ via incremental progress

  July 18, 2024

• Has pharma emerged from the ‘age of uncertainty’?

  July 16, 2024

• As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat

  July 11, 2024

• FDA approval is just the beginning. Now Lilly’s Kisunla faces the tough Alzheimer’s market.

  July 9, 2024

• How BeiGene is taking on established blockbusters with an expanding blood cancer arsenal

  July 2, 2024

• Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections

  June 27, 2024

• Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?

  June 25, 2024

• Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’

  June 18, 2024

• Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now

  June 13, 2024

• As Big Pharma places bigger bets on ADCs, here’s where the field is headed next

  June 11, 2024

• A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers

  June 6, 2024

• Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old

  June 3, 2024

• As Senate’s gaze lands on patents, a former US PTO chief calls the effort a ‘broad misunderstanding’

  May 30, 2024

• Can robots break the cell therapy bottleneck?

  May 29, 2024

• AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets

  May 23, 2024

• Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field

  May 22, 2024

• Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large

  May 16, 2024

• Big Pharma’s most improved drugs: a new generation of blockbusters

  May 14, 2024

• Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown

  May 9, 2024

• AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist

  May 8, 2024

• $4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’

  May 2, 2024

• Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters

  April 30, 2024

• As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply

  April 25, 2024

• How pharma’s surging M&A is impacting the industry’s tech sector

  April 11, 2024

• Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future

  April 9, 2024

• With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition

  April 4, 2024

• A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough

  April 2, 2024

• ‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field

  March 28, 2024

• Alnylam turns to genealogy to find rare disease patients through family trees

  March 26, 2024

• An ocean of answers in a single cell — how proteomics can lead to better drugs

  March 21, 2024

• As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help

  March 19, 2024

• Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

  March 14, 2024

• The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs

  March 12, 2024

• J&J’s growing rare disease focus brings a potential multi-use treatment to the table

  March 7, 2024

• HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

  March 5, 2024

• Biogen partner NeuroSense seeks a role in the ALS revolution

  Feb. 29, 2024

• Can a top scientist and Moderna co-founder change the CRO game?

  Feb. 28, 2024

• AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

  Feb. 22, 2024

• Biden or Trump: How deeply will 2024’s election outcome impact pharma?

  Feb. 20, 2024

• The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

  Feb. 15, 2024

• ‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

  Feb. 14, 2024

• Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

  Feb. 8, 2024

• ‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap

  Feb. 6, 2024

• Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?

  Feb. 1, 2024

• Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?

  Jan. 31, 2024

• King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

  Jan. 25, 2024

• J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff

  Jan. 24, 2024

• How to make 2024 a banner year for biopharma, despite the headwinds

  Jan. 18, 2024

• One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery

  Jan. 10, 2024

• Biopharma’s FTC headache deepens with guideline shifts years in the making

  Dec. 21, 2023

• This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

  Dec. 19, 2023

• The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them

  Dec. 14, 2023

• Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

  Dec. 12, 2023

• Real Chemistry’s CEO on biopharma’s outlook in 2024

  Dec. 7, 2023

• How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

  Nov. 30, 2023

• The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech

  Nov. 28, 2023

• Organon’s chief medical officer wants to change how the world sees women’s health

  Nov. 22, 2023

• AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

  Nov. 16, 2023

• A biotech tackles drug discovery with transcription factor know-how

  Nov. 15, 2023

• How pharma leaders talk about ethics in a highly criticized industry

  Nov. 9, 2023

• The thorniest questions facing pharma, according to a leading bioethicist

  Nov. 6, 2023

• How Big Pharma keeps the oncology engines hot with a host of strategies

  Nov. 2, 2023

• Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

  Oct. 31, 2023

• Red Jacket: Dr. Jeremy Levin, a transformational leader

  Oct. 27, 2023

• Pfizer’s new shot approval adds to a growing vaccine prowess

  Oct. 24, 2023

• Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

  Oct. 19, 2023

• PharmaVoice 100s: Rare disease warriors

  Oct. 16, 2023

• Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

  Oct. 12, 2023

• FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

  Oct. 5, 2023

• PharmaVoice 100s: Cancer care visionaries

  Oct. 2, 2023

• The PharmaVoice 100: Trailblazers

  Sept. 29, 2023

• Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk

  Sept. 28, 2023

• Do humans have a place in pharma’s AI future?

  Sept. 26, 2023

• As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

  Sept. 21, 2023

• Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

  Sept. 15, 2023

• In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

  Sept. 14, 2023

• ‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride

  Sept. 7, 2023

• Finding the right flu vaccine is hard. Getting people to take it is harder.

  Aug. 30, 2023

• ‘We need to do better:’ A biotech CEO on standing apart from the crowd

  Aug. 29, 2023

• ‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

  Aug. 24, 2023

• Henrietta Lacks’ immortal cells put biopharma profits under a microscope

  Aug. 23, 2023

• How an AstraZeneca exec is leading the charge in the next immuno-oncology era

  Aug. 17, 2023

• Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth

  Aug. 10, 2023

• In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

  Aug. 8, 2023

• New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

  Aug. 3, 2023

• How CymaBay overcame a NASH failure for another shot at liver disease success

  Aug. 2, 2023

• Big Pharma CEOs get candid about pricing and M&A

  July 28, 2023

• For Merck, understanding maternal mortality is the first step toward equity

  July 25, 2023

• Google for genes? This AI company aims to curate the entire human genome.

  July 20, 2023

• As biologics boom, here’s how manufacturers are keeping up

  July 19, 2023

• Novo’s workhorse Ozempic could shine in new areas

  July 13, 2023

• Merck’s New Jersey campus is getting a biotech makeover

  July 11, 2023

• Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

  July 7, 2023

• A pharma summer — how leaders unwind and recharge their teams in the warmer months

  June 30, 2023

• Intercept’s NASH retreat is the latest setback for a challenging liver disease

  June 27, 2023

• DIA’s chief exec is on a mission to grow its footprint across healthcare

  June 22, 2023

• AI has secured a footing in drug discovery. Where does it go from here?

  June 20, 2023

• The ingredients of a successful biopharma collaboration

  June 13, 2023

• Yes, biopharma still has a reputation problem. These leaders are looking for solutions.

  June 8, 2023

• Janssen and Legend’s longtime collaboration lands a CAR-T win at ASCO

  June 5, 2023

• How Takeda finds the hottest new science to fuel its oncology work

  June 1, 2023

• From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry

  May 25, 2023

• The power of genetics — how research into gene sequencing could revolutionize biopharma

  May 23, 2023

• Led by the Pfizer-Seagen deal, ADCs are starting to ‘take center stage’

  May 9, 2023

• A biopharma CEO opens up about executive salaries — and why he wants to change the status quo

  May 4, 2023

• From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

  May 2, 2023

• How biopharma dealmaking kicked back into action

  April 27, 2023

• Pharma’s immunology field is full of blockbusters, and it’s just getting started

  April 27, 2023

• Cure Ventures has $350M to pour deep into biotech ‘company building’

  April 20, 2023

• Depression has long been treated chronically — Sage wants to change that

  April 18, 2023

• Fighting vaccine hesitancy may require a new approach from pharma

  April 13, 2023

• Despite J&J’s exit, Big Pharma is closing in on a launch of the first RSV vax this year

  April 6, 2023

• The silver linings in biotech’s wobbly market

  April 4, 2023

• Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

  March 30, 2023

• SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi

  March 28, 2023

• This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once

  March 23, 2023

• SVB’s collapse had limited impact on biopharmas — but a broader financial crisis could change the landscape

  March 21, 2023

• Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back

  March 16, 2023

• A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch

  March 14, 2023

• Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time

  March 9, 2023

• Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?

  March 7, 2023

• The ‘recovering academic’ leading Allogene to the next stage of cell therapy

  March 2, 2023

• Why the pharma industry is digging deep in rare disease

  Feb. 21, 2023

• Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

  Feb. 16, 2023

• The post-COVID outlook for decentralized clinical trials

  Feb. 14, 2023

• Leaps in vax tech — researchers find new ways to tackle old problems like fungal infections and cancer

  Feb. 7, 2023

• Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma

  Feb. 2, 2023

• This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

  Jan. 31, 2023

• Economic crisis? J&J execs say that won’t stop them from hitting $60B target

  Jan. 25, 2023

• AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships

  Jan. 24, 2023

• A Moderna tie-up ushers in new era for CytomX

  Jan. 18, 2023

• Biopharma M&A may get the push it needs in 2023, but with a face lift

  Jan. 12, 2023

• Chinook Therapeutics nears the finish line in kidney disease

  Jan. 10, 2023

• Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

  Jan. 5, 2023

• Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease

  Dec. 22, 2022

• Blood cancer cures aren’t here yet — but incremental combinations bring the field closer

  Dec. 19, 2022

• At the heart of hematology breakthroughs, a community of researchers and patients comes together

  Dec. 13, 2022

• For Duchenne-focused Sarepta, gene therapy is the natural next step

  Dec. 8, 2022

• 5 final FDA action dates to watch this year

  Dec. 1, 2022

• Evommune’s unique method of drug discovery is more than skin deep

  Nov. 29, 2022

• Why the biopharma ‘IPO playbook’ changed in 2022

  Nov. 21, 2022

• Is AI just hype or a real revolution in pharma? It’s complicated

  Nov. 17, 2022

• To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

  Nov. 16, 2022

• 3 ways pharma can weather a recession

  Nov. 10, 2022

• While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

  Nov. 8, 2022

• ‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected

  Nov. 3, 2022

• While DCTs get all the hype, some industry insiders say the future is a digital hybrid

  Nov. 1, 2022

• Riches, rags, riches: Is Biogen the Cinderella of biotechs?

  Oct. 27, 2022

• Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning

  Oct. 24, 2022

• J&J reveals just how much economic turbulence is affecting Big Pharma

  Oct. 20, 2022

• He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

  Oct. 17, 2022

• The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

  Oct. 10, 2022

• Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

  Oct. 3, 2022

• How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

  Sept. 30, 2022

• From the ‘go-go days’ to a bubble crunch — the biotech sector faces its next challenge

  Sept. 12, 2022

• Entrepreneurs: Armon Sharei

  Sept. 6, 2022

• Entrepreneurs: David Katz

  Sept. 6, 2022

• Disrupters: Julie Kim

  Sept. 6, 2022

• Entrepreneurs: Kuldeep Singh Rajput

  Sept. 6, 2022

• Disrupters: Sally Allain

  Sept. 6, 2022

• First 90 Days: Adaptive Biotech’s Tycho Peterson

  Sept. 1, 2022

• The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact

  Aug. 29, 2022

• Patents, pandemics and pricing: a peek at the top drug from every big pharma

  Aug. 22, 2022

• Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

  Aug. 11, 2022

• As pharma M&A ramps up, U.S. execs are bullish on more deals

  Aug. 11, 2022

• Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

  Aug. 4, 2022

• What’s next for Biogen? Here’s what executives are saying

  July 27, 2022

• A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

  July 25, 2022

• With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

  July 21, 2022

• Biotech R&D spending has skyrocketed, and so have opportunities for savings

  July 19, 2022

• Why a 'fundamental shift' in regulatory submissions is on the way

  July 11, 2022

• The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman

  June 29, 2022

• #DIA2022: How the industry's top regulator views the future of healthcare

  June 21, 2022

• First 90 Days: Editas Medicine’s Gilmore O’Neill

  June 13, 2022

• As cancer innovations thrive, patient access is the next piece of the puzzle

  June 8, 2022

• How to build a cancer pipeline: Big Pharma oncology heads on driving science forward

  June 6, 2022

• PBMs under fire for drug prices defend their worth

  May 26, 2022

• Pharmas can be 'more than medicine' by focusing on preventative care

  May 24, 2022

• Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

  May 17, 2022

• With the shine of amyloid fading, tau is a rising star in Alzheimer's

  May 11, 2022

• Ultra-sensitive tests bring biomarkers into the drug development forefront

  May 5, 2022

• The 'innovation gap' haunts Big Pharma, and the race is on for the next blockbusters

  April 28, 2022

• Mouse vs. machine: Using AI to solve the animal testing model in pharma

  April 26, 2022

• A pharma mystery: Cancer-causing impurities drive joint search for answers

  April 19, 2022

• Why the war in Ukraine could accelerate the deglobalization of clinical trials

  April 12, 2022